Millions of Medicare enrollees are likely to see relief in 2025 when a $2,000 cap on out-of-pocket prescription drug-spending ...

With multiple stakeholders involved with different interests, the “specialty drug” definition can be a moving target.

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...

The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...

For pharmacy benefit managers, our new Congress should focus on removing the flawed rules to improve the game rather than ...

• Expects to Achieve 2024 Guidance of $158 - $162 Million in Revenue and $32 - $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million • Aiming to Secure New Business Development and M&A ...

Major insurers say the deals are essential to controlling costs, but critics say they may be driving up costs and unfairly ...

After years of restructuring, Chicago-based Exicure has South Korean majority ownership and is buying the U.S. arm of a South ...

Say it's a drug pressure medication, and you can say, 'Can you make sure you can prescribe something that's on my plan ... where she covers business and personal finance.

Clene will meet with the FDA in early 2025 to review and finalize its statistical analysis plan for the EAP NfL biomarker analyses. Survival Pharmacometric Modeling: Provide analyses of NfL and ...

The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...